BioAge Labs (BIOA) Liabilities and Shareholders Equity (2023 - 2026)

BioAge Labs (BIOA) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $397.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 15.65% year-over-year to $397.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 26.97% YoY), and the FY2025 full-year result was $294.9 million, down 17.68% from the prior year.
• Liabilities and Shareholders Equity climbed to $397.7 million in Q1 2026, from $294.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $397.7 million in Q1 2026 to a low of $25.9 million in Q4 2023.
• A 4-year average of $298.1 million and a median of $329.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 1281.86% in 2024 and retreated 17.68% in 2025, its largest moves.
• Tracing BIOA's Liabilities and Shareholders Equity over 4 years: stood at $25.9 million in 2023, then jumped by 1281.86% to $358.2 million in 2024, then decreased by 17.68% to $294.9 million in 2025, then surged by 34.85% to $397.7 million in 2026.
• Business Quant data shows BIOA's Liabilities and Shareholders Equity at $397.7 million in Q1 2026, $294.9 million in Q4 2025, and $305.1 million in Q3 2025.